NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to approve its immunotherapy Ebvallo. Read more here.

Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after ... was achieved upon treatment of EBV+ PTLD patients with the drug. As the next steps in the regulatory process, Atara ...

Shares of Atara Biotherapeutics (NASDAQ:ATRA) continued to trade lower in the premarket on Tuesday after the U.S. Food and Drug Administration (FDA) slapped the cell therapy developer with a ...

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) active Investigational New Drug (IND) applications. These INDs include the ...

Investing.com -- Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) tumbled 51% after the company disclosed receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ...

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) active Investigational New Drug (IND) applications. These INDs ...

While the ATA3219 drug product is manufactured at a separate ... in funding through an equity line of credit. Price Action: ATRA stock is down 4.09% at $6.302 at last check Tuesday.